Protein FAM53B isoform 2 peptide presented on HLA class I (FAM53B-219aa-HLA)

Protein FAM53B isoform 2 (219aa) is a member of the FAM53 family, primarily known for its role in the regulation of the Wnt/beta-catenin signaling pathway (UniProt Q6NVV9) [1]. It functions by interacting with beta-catenin and modulating its nuclear translocation, which is a critical step in oncogenic signaling and cell proliferation (NCBI Gene) [2]. In various malignancies, such as melanoma and certain solid tumors, this 219-amino acid isoform is overexpressed, and its degradation products are processed and presented on the cell surface by Human Leukocyte Antigen (HLA) Class I molecules (Immatics) [3]. This specific peptide-HLA complex acts as a tumor-associated antigen (TAA), making it a viable target for advanced immunotherapies. Current therapeutic strategies focus on developing T-cell receptor (TCR) engineered T-cell therapies that can specifically recognize and eliminate cells presenting this antigen (Patent WO2020053281A1) [4]. The therapeutic potential of targeting the FAM53B-219aa complex lies in its differential expression between cancerous and healthy tissues, providing a window for targeted intervention with reduced off-target toxicity.

Other names

KIAA0140Protein FAM53B isoform 2Family with sequence similarity 53 member B isoform 2FAM53B-219aaFAM53B-HLA complex

T-cell receptor (TCR) mediated recognition of the specific FAM53B peptide presented by HLA class I molecules, leading to cytotoxic T-lymphocyte (CTL) activation and targeted lysis of tumor cells.